Increasing Patient Diversity in Clinical Trials
It has become imperative for companies in the health care space to ensure the inclusion of diverse populations in clinical trials as a representative part of the patient population. Companies guaranteeing diverse trail across the board in products, drugs and medical devices trials allows for a greater potential to for affective medical interventions. Diabetes, for example, disproportionately affects Hispanics and African Americans: a company manufacturing a drug to address diabetes should ensure they have an accurate representation of the affected populations in their clinical trials to ensure efficacy and safety of their product. Join JLABS @ NYC for a panel discussion that examines the need and pathway to creating diversity in their clinical trials. During this event, you’ll hear from a various leaders as they offer insights into their own experiences in this space and perspectives on how we can continue to move the needle in the right direction..
Space is limited please register here.
Use the promo code NYCPartner for a 35% discount
Participating Representatives:
Enrique Arbelaez |Co-Founder & Managing Partner, CIEN+
Fabian Sandoval | CEO & Research Director, Emerson Clinical Resource Institute
Carmen White | IPE Program Manager, Janssen R&D
Staci Hargraves | VP, R&D Operations, Planning and Strategy, Janssen R&D
Kellie Terry | Associate Director, Clinical Functional Planning Leader, Janssen R&D
Questions?
Contact: Julia Huettner-Pumar Jhuettne@its.jnj.com
